GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway.
CONCLUSIONS GANT61 and valproic acid inhibited multiple myeloma cell proliferation synergistically by inhibiting the Hedgehog signaling pathway. The present study may provide a combination regime for the therapy of multiple myeloma. PMID: 32054823 [PubMed - in process]
Conditions: Cardiac Disease; Multiple Myeloma Intervention: Sponsor: Wuhan Asia Heart Hospital Not yet recruiting
Investigators from China reported the first case of COVID-19 in a patient with multiple myeloma who was successfully treated with the humanized anti-IL-6 receptor antibody tocilizumab.Medscape Medical News
Contributors : Ram K Singh ; Robert Z OrlowskiSeries Type : Expression profiling by arrayOrganism : Homo sapiensDeletion (Del) of 17p involving the TP53 tumor suppressor remains an adverse prognostic factor in multiple myeloma, and more effective targeted therapies are needed for these patients. Genomic studies revealed that del17p was associated with reduced copy number and mRNA expression of RNA polymerase II subunit alpha (POLR2A), which is located near TP53. We therefore studied HDP-101, an anti-B-cell maturation antigen (BCMA) antibody drug conjugate (ADC) with the POLR2A poison α-amanitin, which showed potent a...
Conclusions: When compared with Kd27 BIW, Kd70 QW is the optimal dose that represents a cost-effective utilization of health care budget with incremental CE ratios well below the accepted willingness-to-pay thresholds in the US. PMID: 32249621 [PubMed - as supplied by publisher]
Authors: Chan TS, Hwang YY, Tse E Abstract Introduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless, patients with hematological cancers receive less attention as compared with their solid tumor counterparts regarding this potentially fatal complication.Areas covered: Risk factors that are associated with the development of VTE in hematological cancers are discussed, based on a PubMed literature search. Since different hematological malignancies carry different risk of VTE, risk assessment in individual types of hematological cancers, including acute leukemia...
A monoclonal antibody that targets the CD38 receptor on multiple myeloma cells has been approved for adults who ’ve received at least 2 prior treatments for the incurable blood cancer.
Renal failure is a serious complication associated with multiple myeloma that can occur in up to 50% of cases at diagnosis.1 Although the introduction of novel antimyeloma agents has improved outcomes, severe renal impairment is still associated with an early risk of death in patients with multiple myeloma.2,3 Renal injury occurs in multiple myeloma secondary to the direct toxic effect of monoclonal light chains precipitating in the renal tubules.4 Other potential contributors to myeloma-related renal impairment include hypercalcemia, dehydration, and use of nephrotoxic agents such as analgesics, antibiotics, and contrast dye.
Light chain deposition disease (LCDD) is commonly associated with monoclonal gammopathy of renal significance (MGRS). Venetoclax is a Bcl-2 inhibitor approved for the treatment of chronic lymphocytic leukemia with activity against multiple myeloma and AL amyloidosis clones that harbor the t(11;14) abnormality. Here, we report the first use of venetoclax in a patient with LCDD secondary to MGRS after kidney transplantation. A 43 year-old male presented with 17.9 g/d of proteinuria and creatinine of 3.7 mg/dl.
Previous old reports suggested that a higher bone marrow plasma cell percentage (BMPC%) was associated with worse outcomes. However, it is unknown if BMPC % was an independent predictor, as the genetic information was not available at that time. Currently, the impact of BMPC% at diagnosis of multiple myeloma (MM) is not well described.
Publication date: Available online 5 April 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Josep-Maria Ribera, Olga García, Eduardo Cerello Chapchap, Cristina Gil, José González-Campos, Pere Barba, María-Luz Amigo, María-José Moreno, Esperanza Lavilla, Natalia Alonso, Juan-Miguel Bergua, Mar Tormo, Jordi Ribera, Magdalena Sierra, Daniel Martínez-Carballeira, Santiago Mercadal, Jesús-María Hernández-Rivas, Ferran Vall-llovera, Eulàlia Genescà, Antònia Cladera